Products - Renal cancer | Topic | NICE

Showing 8 products

Date | Title

New and updated: New in the last 6 monthsRemove ‘New and updated: New in the last 6 months’ filter

Belzutifan for treating tumours associated with von Hippel-Lindau disease (TA1011)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
16 October 2024
Avelumab with axitinib for untreated advanced renal cell carcinoma (MA review of TA645) [ID6294]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
25 June 2025
Belzutifan for previously treated advanced renal cell carcinoma [ID6154]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Kidney Cancer
Status:
In development
Programme:
NICE guideline
Expected publication date:
TBC
Cabozantinib with nivolumab and ipilimumab for untreated intermediate- or poor-risk advanced renal cell carcinoma [ID6330]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Subcutaneous nivolumab for treating advanced renal cell carcinoma after systemic treatment TSID 12008
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Signatera molecular residual disease assay (MT741)
Status:
Topic selection
Programme:
Medical technologies guidance
Expected publication date:
TBC
Belzutifan with lenvatinib for treating advanced renal cell carcinoma after a PD-1 or PD-L1 inhibitor ID 6476
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC